Protective Effects of Astragalus Polysaccharide on Sepsis-Induced Acute Kidney Injury.
Journal
Analytical cellular pathology (Amsterdam)
ISSN: 2210-7185
Titre abrégé: Anal Cell Pathol (Amst)
Pays: United States
ID NLM: 101541993
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
05
2020
revised:
06
01
2021
accepted:
12
01
2021
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
17
11
2021
Statut:
epublish
Résumé
To explore the protective roles of Astragalus polysaccharide (APS) on acute renal injury (AKI) induced by sepsis. Firstly, an animal model of sepsis-induced AKI was established by injecting lipopolysaccharide (LPS) into mice. The mice were pretreated with an intraperitoneal injection of 1, 3, and 5 mg/(kg·d) APS for 3 consecutive days. The severity of kidney injury was then scored by histopathological analysis, and the concentrations of serum urea nitrogen (BUN) and serum creatinine (SCr) and the levels of tumor necrosis factor In vivo experiments in mice showed that APS can reverse LPS-induced kidney damage in a concentration-dependent manner ( APS could alleviate sepsis-induced AKI by regulating inflammation, apoptosis, ERS, and EMT.
Identifiants
pubmed: 33575163
doi: 10.1155/2021/7178253
pmc: PMC7857912
doi:
Substances chimiques
Endoplasmic Reticulum Chaperone BiP
0
HSPA5 protein, human
0
Hspa5 protein, mouse
0
Polysaccharides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7178253Informations de copyright
Copyright © 2021 Jie Sun et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Sci Technol Adv Mater. 2019 Nov 26;20(1):1164-1177
pubmed: 32082438
Am J Chin Med. 2016;44(1):1-22
pubmed: 26916911
Nephron Exp Nephrol. 2009;112(1):e1-9
pubmed: 19342868
Biochim Biophys Acta Mol Basis Dis. 2017 Oct;1863(10 Pt B):2534-2545
pubmed: 28219766
Sci Rep. 2015 Jul 07;5:11822
pubmed: 26149595
Front Pharmacol. 2016 Dec 06;7:479
pubmed: 27999546
Ren Fail. 2016 Jun;38(5):831-7
pubmed: 27001462
Biomed Res Int. 2020 Jan 3;2020:2851349
pubmed: 31998784
Biosci Rep. 2020 Jan 31;40(1):
pubmed: 31894851
Nat Rev Nephrol. 2017 Mar;13(3):143-151
pubmed: 28090081
Neuropeptides. 2017 Feb;61:31-37
pubmed: 27522536
Immunopharmacol Immunotoxicol. 2015;37(5):428-33
pubmed: 26376109
Mediators Inflamm. 2018 Jun 14;2018:9413876
pubmed: 30013453
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Nat Rev Mol Cell Biol. 2012 Jan 18;13(2):89-102
pubmed: 22251901
J Am Soc Nephrol. 2014 Dec;25(12):2689-701
pubmed: 24925726
Chin Med J (Engl). 2013 Dec;126(23):4409-16
pubmed: 24286398
Crit Care. 2014 Sep 27;18(5):520
pubmed: 25261195
Evid Based Complement Alternat Med. 2014;2014:271862
pubmed: 24711851
Ann Intensive Care. 2016 Dec;6(1):56
pubmed: 27334720
Crit Care. 2007;11(2):R31
pubmed: 17331245
Kidney Int. 2019 Nov;96(5):1083-1099
pubmed: 31443997
Lancet. 2015 Oct 10;386(10002):1465-71
pubmed: 26466051
Exp Ther Med. 2019 Dec;18(6):4707-4717
pubmed: 31777559
J Ethnopharmacol. 2017 Jul 31;207:184-191
pubmed: 28648928
J Physiol. 2018 Aug;596(16):3603-3616
pubmed: 29863758
EBioMedicine. 2018 May;31:217-225
pubmed: 29759484
J Am Soc Nephrol. 2004 Jan;15(1):1-12
pubmed: 14694152
Crit Care. 2008;12(2):R42
pubmed: 18364044
Exp Ther Med. 2017 Oct;14(4):3127-3130
pubmed: 28912862